Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M386Revenue $M12.0Net Margin (%)-767.7Z-Score-1.0
Enterprise Value $M356EPS $-2.9Operating Margin %-515.2F-Score4
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-767.7Higher ROA y-yY
Price/Book13.110-y EBITDA Growth Rate %0Quick Ratio2.7Cash flow > EarningsY
Price/Sales15.15-y EBITDA Growth Rate %0Current Ratio3.0Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-83.1Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-275.7Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M42.1ROI % (ttm)-96.2Gross Margin Increase y-yN

Gurus Latest Trades with SUPN

Number of guru portfolios checked: 56.

No Entry found!

SUPN is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!

SUPN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Bhatt Padmanabh P.Sr. VP of IP; CSO 2013-08-19Sell2,285$8.2111.81 view
BIGHAM MICHAELDirector 2013-03-22Buy35,000$5.4169.69 view
SIEBERT JOHN MDirector 2013-03-21Buy3,000$5.566.91 view
Khattar Jack A.President, CEO 2013-03-15Buy10,000$6.1549.27 view
PATRICK GREGORY SVP, CFO 2013-03-14Buy5,000$6.9532.09 view
ORBIMED ADVISORS LLC10% Owner 2013-02-13Sell302,183$7.5521.59 view
ORBIMED ADVISORS LLC10% Owner 2012-12-18Sell297,815$6.9232.66 view
SIEBERT JOHN MDirector 2012-12-04Buy7,000$8.1412.78 view
Abingworth Management LTD10% Owner 2012-05-04Buy1,100,000$583.6 view
ORBIMED ADVISORS LLCDirector, 10% Owner 2012-05-04Buy1,100,000$583.6 view

Press Releases about SUPN :

    Quarterly/Annual Reports about SUPN:

    News about SUPN:

    Articles On GuruFocus.com
    Supernus Pharmaceuticals Reports Insider Buys Mar 26 2013 

    More From Other Websites
    Supernus Up on Non-Dilutive Royalty Deal Jul 10 2014
    SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Jul 08 2014
    Supernus to Receive $30 Million in Non-Dilutive Royalty Deal Jul 08 2014
    Supernus to Receive $30 Million in Non-Dilutive Royalty Deal Jul 08 2014
    How Supernus Pharmaceuticals (SUPN) Stock Stands Out in a Strong Industry Jun 11 2014
    SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security... May 22 2014
    Milestone Payment for Supernus May 22 2014
    Supernus to Present at Jefferies Healthcare Conference in June May 21 2014
    Supernus Receives $2 Million Milestone for United Therapeutics' Launch of Orenitram(TM) May 20 2014
    Why I'm Long Supernus, A Small Specialty Pharma Company May 20 2014
    Discovery Group reports 5.5% stake in Supernus May 14 2014
    Supernus Pharmaceuticals' (SUPN) CEO Jack Khattar on Q1 2014 Results - Earnings Call Transcript May 13 2014
    SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 13 2014
    Supernus sees FY14 revenue $75M-$85M, consensus $77.67M May 12 2014
    Supernus reports Q1 EPS (38c), consensus (41c) May 12 2014
    Supernus Announces First Quarter 2014 Results May 12 2014
    Q1 2014 Supernus Pharmaceuticals Earnings Release - After Market Close May 12 2014
    SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 30 2014
    Supernus to Host First Quarter 2014 Earnings Conference Call Apr 29 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    Email Hide